glp 1 uniprot RCSB PDB nupure Proba GLP-1 Metabolism Pro
Description
An exploratory post-hoc analysis of trial results suggested that those with milder disease exhibited a better response to exenatide
How will they change obesity care
Using the Wrong Water: A researcher, in a rush, grabs sterile water instead of bacteriostatic water for a vial they plan to use for a month
Severe or persistent injection site reactions leading to treatment discontinuation are uncommon in clinical trials
AZD6234 , an original development by AstraZeneca, is a long-acting insulin receptor agonist and CALCR receptor agonist intended for clinical development in the treatment of obesity
The STEP 1 trial extension showed substantial weight regain after semaglutide was stopped, even with lifestyle guidance
